Skip to content
Research Article Open access CC BY 3.0

Low Prevalence of Metabolic Syndrome in a Group of Patients with Chronic Psychotic Disorders Taking Antipsychotic Polypharmacy in Residential Treatment While Adhering to a Mediterranean Diet

Fernando Espi Forcen, Joaquin Nieto Munuera, Raimundo Munoz Perez, Juan R. Jaramillo, Tatiana Falcone

Journal of Scientific Research and Reports · pp. 1703–1709 · Published 21 May 2014

10.9734/JSRR/2014/10190

Abstract

The aim of this abbreviated report is to describe the prevalence of the Metabolic Syndrome (MS) in a sample group of patients with psychosis in residential treatment in Spain, who have been treated with antipsychotic polypharmacy for 5 years or more. We designed a cross sectional study to describe the prevalence of MS in a population sample of 21 of such patients. Using the criteria recommended by the Third Report of the National Cholesterol Education program Expert panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (NCP-ATP III), In this group 19, 04% of these patients met such criteria. The prevalence is much smaller than those reported in other countries, especially the U.S. This is even more remarkable, given the use of antipsychotic polypharmacy in this sample group of patients, which is an additional risk factor for the development of M.S. Residential treatment (a controlled living environment), Mediterranean diet, tobacco restriction and continuous medical supervision may have contributed to these results. We further inquire whether these factors could protect patients against MS.

Metabolic syndrome psychosis mediterranean diet prevention.

References (15)

  1. 1 Long-Chain ω-3 Fatty Acids for Indicated Prevention of Psychotic Disorders [DOI]
  2. 2 Adherence to Mediterranean diet and risk of developing diabetes: prospective cohort study [DOI]
  3. 3 Increasing off‐label use of antipsychotic medications in the United States, 1995–2008 [DOI]
  4. 4 Adherence to the Mediterranean Diet and Risk of Coronary Heart Disease in the Spanish EPIC Cohort Study [DOI]
  5. 5 Does antipsychotic polypharmacy increase the risk for metabolic syndrome? [DOI]
  6. 6 Virgin Olive Oil Study (VOLOS): vasoprotective potential of extra virgin olive oil in mildly dyslipidemic patients [DOI]
  7. 7 Health Benefits of Mediterranean Diet [DOI]
  8. 8 Prevalence of metabolic syndrome among Australians with severe mental illness [DOI]
  9. 9 Abnormal glucose metabolism in patients treated with antipsychotics [DOI]
  10. 10 High prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia [DOI]
  11. 11 Prevalence of Metabolic Syndrome in Hispanic and Non-Hispanic Patients With Schizophrenia [DOI]
  12. 12 Prevalence of the Metabolic Syndrome in Veterans with Schizophrenia [DOI]
  13. 13 Metabolic syndrome in female patients with schizophrenia treated with second generation antipsychotics: a 3-month follow-up [DOI]
  14. 14 Combined Effects of Tobacco Smoke Exposure and Metabolic Syndrome on Cardiovascular Risk in Older Residents of China [DOI]
  15. 15 Gene–Environment Interaction and the Metabolic Syndrome [DOI]

Cited by 0

No indexed citations yet.

Related research

Article metrics

Real usage data collected on this platform.

51

Page views

0

PDF downloads

34

Outbound clicks

0

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.